EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The MiR-200c/FOXP3 Network: A Promising Biomarker for Predicting Trastuzumab Response in HER2-Positive Breast Cancer

Mohamed S Othman, Mohamed Tharwat Elabbasy, Ahmed M Aref, Aya A Altaleb, Marwa Hamdy Mohammed, Doaa Atef Mohamed Soliman, Nashwa El-Khazragy iD

Technology in Cancer Research & Treatment · 2024-10 · 23

DOI: 10.1177/15330338241292226 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 21.10.2024. Verfasst von Mohamed S Othman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, College of Medicine, University of Ha'il, Ha'il, Saudi Arabia. Hauptthemen laut MEDLINE: Trastuzumab, Breast Neoplasms, Forkhead Transcription Factors, Biomarkers, Tumor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Resistance to Trastuzumab is a significant challenge in the management of HER2-positive Metastatic Breast cancer (HER2-MBC), and a better understanding of the molecular causes of resistance is required to develop more effective treatment plans. While elevated plasma levels of miR-200 and FOXP3 have been linked to breast cancer progression and treatment response, no clinical studies have confirmed these results.

Methods

The study involved 40 patients with HER2-positive metastatic breast cancer (HER2-MBC). The expression levels of miR-200c-3p and the FOXP3 gene were assessed in plasma samples at two time points: baseline (BL) and after the consent completion of one cycle of Trastuzumab, utilizing quantitative polymerase chain reaction (qPCR). Clinical response to Trastuzumab was evaluated 12 months post-therapy and correlated with the time to progression (TTP) through Kaplan-Meier analysis.

Results

Low plasma expression level of miR-200c-3p was detected before therapy in HER2-MBC, compared to healthy controls, and decreased dramatically in the follow-up sample at disease progression, while increased after one cycle of Trastuzumab therapy in patients who were sensitive to Trastuzumab. At baseline, a low expression level of miR-200c was significantly associated with overexpression of FOXP3, poor prognosis, and shorter time to progression.

Conclusions

The findings suggest that miR-200c-3p may be a promising biomarker for predicting the response to Trastuzumab in HER2-MBC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabBreast NeoplasmsForkhead Transcription FactorsBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesMicroRNAsHumansFemaleMiddle AgedPrognosisGene Expression Regulation, NeoplasticAntineoplastic Agents, ImmunologicalAdultAgedDrug Resistance, NeoplasmKaplan-Meier EstimateTreatment OutcomeGene Regulatory Networks

Stichwörter der Autor:innen

FOXP3HER2-positive breast cancerTrastuzumabdrug resistancemetastatic breast cancermiR-200cpredictor biomarker

Substanzen

TrastuzumabForkhead Transcription FactorsBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesMicroRNAsAntineoplastic Agents, ImmunologicalMIRN200 microRNA, humanFOXP3 protein, humanERBB2 protein, human

Autor:innen und Institutionen

  • Department of Biochemistry, College of Medicine, University of Ha'il, Ha'il, Saudi Arabia.
  • College of Medicine, University of Ha'il, Ha'il, Saudi Arabia.
  • Faculty of Biotechnology, October University for Modern Sciences and Arts, Giza, Egypt.
  • College of Medicine, Gazi University, Ankara, Turkey.
  • Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • Department of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

ORCID-Profile: Nashwa El-Khazragy

Zitieren

APA

Othman, M. S., Elabbasy, M. T., Aref, A. M., Altaleb, A. A., Mohammed, M. H., Soliman, D. A. M., & El-Khazragy, N. (2024). The MiR-200c/FOXP3 Network: A Promising Biomarker for Predicting Trastuzumab Response in HER2-Positive Breast Cancer. Technology in Cancer Research & Treatment, 23. https://doi.org/10.1177/15330338241292226

Vancouver

Othman MS, Elabbasy MT, Aref AM, Altaleb AA, Mohammed MH, Soliman DAM, et al. The MiR-200c/FOXP3 Network: A Promising Biomarker for Predicting Trastuzumab Response in HER2-Positive Breast Cancer. Technology in Cancer Research & Treatment. 2024;23. doi:10.1177/15330338241292226

BibTeX
@article{Othman2024,
  author = {Othman, Mohamed S and Elabbasy, Mohamed Tharwat and Aref, Ahmed M and Altaleb, Aya A and Mohammed, Marwa Hamdy and Soliman, Doaa Atef Mohamed and El-Khazragy, Nashwa},
  title = {The MiR-200c/FOXP3 Network: A Promising Biomarker for Predicting Trastuzumab Response in HER2-Positive Breast Cancer},
  journal = {Technology in Cancer Research & Treatment},
  year = {2024},
  volume = {23},
  doi = {10.1177/15330338241292226}
}
Kostenlos starten →